FBRX · As filed with the SEC
Forte Biosciences income statement, by fiscal year
The statement as Forte Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations and Comprehensive Loss · USD, except per-share amounts
| USD, except per-share amounts | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating expenses: | ||||||||
| Research and development | — | — | — | — | — | — | 45,299,000 | 51,080,000 |
| Research and development | 57,647,000 | 20,714,000 | 21,862,000 | 5,594,000 | 13,853,000 | 10,004,000 | — | — |
| Research and development - related party | 600,000 | 479,000 | — | — | — | — | — | — |
| General and administrative | 12,410,000 | 15,409,000 | 10,624,000 | 8,302,000 | 7,633,000 | 4,221,000 | 16,248,000 | 12,809,000 |
| In-process research and development assets acquired | — | — | — | — | — | 32,057,000 | — | — |
| Total operating expenses | 70,657,000 | 36,602,000 | 32,486,000 | 13,896,000 | 21,486,000 | 46,282,000 | 61,547,000 | 63,889,000 |
| Loss from operations | (70,657,000) | (36,602,000) | (32,486,000) | (13,896,000) | (21,486,000) | (46,282,000) | (61,511,000) | (45,853,000) |
| Interest income | — | — | — | — | — | — | 1,564,000 | 1,534,000 |
| Interest expense | — | — | — | — | — | — | (3,820,000) | (2,937,000) |
| Loss on disposal of assets | — | — | — | — | — | — | (1,187,000) | — |
| Gain on lease modification | — | — | — | — | — | — | 1,439,000 | — |
| Interest income | 2,715,000 | 1,314,000 | 1,124,000 | — | — | — | — | — |
| Other expense, net | (396,000) | (190,000) | (114,000) | 17,000 | 222,000 | (205,000) | — | — |
| Total other income, net | 2,319,000 | — | — | — | — | — | — | — |
| Net loss before taxes | (68,338,000) | — | — | — | — | — | (63,515,000) | (47,256,000) |
| Income tax expense | 1,037,000 | — | — | — | — | — | 1,000 | 1,699,000 |
| Net loss | (69,375,000) | (35,478,000) | (31,476,000) | (13,879,000) | (21,708,000) | (46,487,000) | (63,516,000) | (48,955,000) |
| Net unrealized gain (loss) on investments | — | — | — | — | — | — | 33,000 | 11,000 |
| Net loss per share - basic and diluted | — | — | — | — | (1.55) | (6.32) | (2.69) | (2.44) |
| Weighted average shares outstanding, basic and diluted | — | — | — | — | 13,967,818 | 7,358,931 | 23,630,422 | 20,059,541 |
| Net loss per share - basic | (4.71) | (12.17) | (1) | (0.8) | — | — | — | — |
| Net loss per share - diluted | (4.71) | (12.17) | (1) | (0.8) | — | — | — | — |
| Weighted average shares outstanding, basic | — | — | — | 17,383,531 | — | — | — | — |
| Weighted average shares outstanding, diluted | — | — | — | 17,383,531 | — | — | — | — |
| Weighted average shares and pre-funded warrants outstanding, basic | 14,717,734 | 2,915,894 | 31,571,039 | — | — | — | — | — |
| Weighted average shares and pre-funded warrants outstanding, diluted | 14,717,734 | 2,915,894 | 31,571,039 | — | — | — | — | — |
| Comprehensive Loss: | ||||||||
| Net loss | (69,375,000) | (35,478,000) | (31,476,000) | — | — | — | — | — |
| Unrealized (loss) gain on available-for-sale securities, net | (8,000) | 7,000 | 4,000 | — | — | — | — | — |
| Comprehensive loss | (69,383,000) | (35,471,000) | (31,472,000) | — | — | — | (63,483,000) | (48,944,000) |
| License revenue | — | — | — | — | — | — | 36,000 | 18,036,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.